natgillin/translations-raw huggingface dataset:
Administration of the oral contraceptive 35 minutes after exenatide did not affect AUC but resulted in a reduction of the Cmax of ethinyl estradiol by 45 %, and Cmax of levonorgestrel by 27-41 %, and a delay in tmax by 2-4 h due to delayed gastric emptying.
Dajanje peroralnega kontraceptiva 35 minut po dajanju eksenatida ni vplivalo na AUC, vendar je povzročilo znižanje Cmax etinildiestrola za 45 % in Cmax levonorgestrela za 27-41 % ter zakasnitev tmax za 2-4 ure zaradi upočasnjenega praznjenja želodca.
Administration of the potent CYP3A4 inducer rifampicin (300 mg twice daily for 9 days) to healthy female volunteers markedly decreased Cmax and AUC of ulipristal acetate and its active metabolite by 90% or more and decreased ulipristal acetate half-life by 2.2-fold corresponding to an approximately 10-fold decrease of ulipristal acetate exposure.
Uporaba močnega induktorja CYP3A4, rifampicina (300 mg dvakrat dnevno 9 dni), je pri zdravih prostovoljkah znatno zmanjšala Cmax in AUC ulipristalacetata ter njegovega aktivnega presnovka za 90 % ali več in 2,2-kratno zmanjšala razpolovni čas ulipristalacetata, kar je enako približno 10- kratnemu zmanjšanju izpostavljenosti ulipristalacetatu.
Administration of the product at overdose (up to 5-fold of the recommended dose for 6 months) resulted in marked reductions in blood pressure, decreases in red blood cell count (effects attributable to the pharmacological activity of the product) and increases in Blood Urea Nitrogen (BUN).
Dajanje prevelikega odmerka zdravila (do 5-kratni priporočeni odmerek 6 mesecev) je povzročilo bistveno znižanje krvnega tlaka, znižanje števila rdečih krvnih celic (učinki, ki se pripisujejo farmakološki aktivnosti zdravila) in zvišanje sečnine v krvi.
Administration of the product at overdose (up to 5-fold of the recommended dose for 6 months) resulted in marked reductions in blood pressure, decreases in red blood cell count (effects attributable to the pharmacological activity of the product) and increases in Blood Urea Nitrogen (BUN; nitrogen containing waste products in the blood).
Dajanje prevelikega odmerka zdravila (do 5-kratni priporočeni odmerek 6 mesecev) je povzročilo bistveno znižanje krvnega tlaka, znižanje števila rdečih krvnih celic (učinki, ki se pripisujejo farmakološki aktivnosti zdravila) in zvišanje sečnine (odpadnih snovi v krvi, ki vsebujejo dušik) v krvi.
Administration of the product by the subcutaneous route in cattle and the intramuscular route in pigs is well tolerated; only a slight transient swelling at the injection site following subcutaneous administration was observed in cattle treated in clinical studies
Subkutano dajanje zdravila pri govedu in intramuskularno pri prašičih živali dobro prenašajo; pri govedu, zdravljenih v kliničnih raziskavah so opazili le blago prehodno oteklino na mestu po subkutanem injiciranju.
Administration of the product in accordance with the recommended monthly dosing schedule for a period of up to 6.5 months resulted in an improvement in lameness and quality of life in dogs with established osteoarthritis, as assessed by the dogs’ owners.
Uporaba zdravila v skladu s priporočenim načrtom mesečnega odmerjanja za obdobje do 6,5 meseca je po ocenah lastnikov psov pokazala izboljšanje hromosti in kakovosti življenja pri psih, obolelih z osteoartritisom.
Administration of the recommended dose (4 drops per ear) 5 times daily for 21 consecutive days to dogs weighing 7.6 to 11.4 kg bodyweight caused a slight decrease in serum cortisol response after adrenocorticotropic hormone (ACTH) administration in an ACTH stimulation test.
Uporaba priporočenega odmerka (4 kapljice na uho) petkrat dnevno 21 zaporednih dni, je pri psih težkih 7,6 do 11,4 kg po adrenokortikotropični hormonski stimulaciji povzročila rahel padec serumske koncentracije kortizola.
Administration of the reconstituted solution:
Aplikacija pripravljene raztopine
Administration of the veterinary medicinal product by the subcutaneous route in cattle and the intramuscular route in pigs is well tolerated; only a slight transient swelling at the injection site following subcutaneous administration was observed in cattle treated in clinical studies
Subkutano dajanje zdravila pri govedu in intramuskularno pri prašičih živali dobro prenašajo; pri govedu, zdravljenih v kliničnih raziskavahso opazili le blago prehodno oteklino na mestu po subkutanem injiciranju
Administration of the ZALTRAP/FOLFIRI should be delayed until platelet count is 75 x 109/L (see section 4.2).
Uporabo kombinacije ZALTRAP/FOLFIRI je treba odložiti, dokler ni število trombocitov  75 x 109/l (glejte poglavje 4.2).
Administration of tolvaptan may cause too rapid increases in serum sodium (≥ 12 mmol/l per 24 hours, please see below); therefore, monitoring of serum sodium in all patients should start no later than 4-6 hours after treatment initiation.
Dajanje tolvaptana lahko povzroči prehitro povečanje natrija v serumu (≥ 12 mmol/l na 24 ur, glejte spodaj); zato je treba z nadziranjem natrija v serumu pri vseh bolnikih začeti najkasneje 4 – 6 ur po uvedbi zdravljenja.
Administration of trastuzumab emtansine was well tolerated in rats and monkeys at doses up to 20 and 10 mg/kg, respectively, corresponding to 2040 g DM1/m2 in both species, which is approximately equivalent to the clinical dose of trastuzumab emtansine in patients.
Podgane in opice so uporabo trastuzumaba emtanzina dobro prenašale v odmerkih do 20 mg/kg (podgane) in 10 mg/kg (opice); to pri obeh vrstah ustreza 2040 g DM1/m2 in je približno enakovredno kliničnemu odmerku trastuzumaba emtanzina pri bolnikih.
Administration of trimethoprim/sulphamethoxazole 160 mg/800 mg increased lamivudine exposure by about 40 %.
Po dajanju 160 mg trimetoprima/800 mg sulfametoksazola se je izpostavljenost lamivudinu povečala za 40 %.
Administration of Truvada every 48 hours is recommended based on modelling of single-dose pharmacokinetic data for emtricitabine and tenofovir disoproxil fumarate in non-HIV infected subjects with varying degrees of renal impairment (see section 4.4).
Priporočljiv je odmerek zdravila Truvada vsakih 48 ur, kar temelji na podatkih o farmakokinetiki enkratnih odmerkov za emtricitabin in dizoproksiltenofovirijev fumarat pri osebah, ki niso okužene s HIV, z različnimi stopnjami ledvične okvare (glejte poglavje 4.4).
Administration of Truvada with food resulted in a delay of approximately three quarters of an hour in reaching maximum tenofovir concentrations and increases in tenofovir AUC and Cmax of approximately 35% and 15%, respectively, when administered with a high fat or light meal, compared to administration in the fasted state.
Jemanje zdravila Truvada s hrano se je odražalo v približno tričetrturni zakasnitvi pri doseganju maksimalne koncentracije tenofovirja ter povečanju AUC tenofovirja za približno 35% in Cmax za približno 15% pri jemanju ob z maščobami bogatem ali lažjem obroku, v primerjavi z jemanjem na tešče.
Administration of umeclidinium bromide may produce paradoxical bronchospasm that may be life- threatening.
Uporaba umeklidinijevega bromida lahko povzroči paradoksni bronhospazem, ki je lahko smrtno nevaren.
Administration of unconjugated pneumococcal polysaccharides at 13 months following the primary series with Prevenar elicited an anamnestic antibody response for the 7 serotypes included in the vaccine, indicating that priming had occurred.
Dajanje nekonjugiranih pnevmokoknih polisaharidov pri 13 mesecih po primarnem zaporedju cepljenja s cepivom Prevenar je izzvalo spominski protitelesni odziv na vseh 7 v cepivo vključenih serotipov, kar kaže, da je bilo prvo cepljenje uspešno.
Administration of Velosulin is also possible by subcutaneous or intravenous injection.
Velosulin je mogoce aplicirati tudi v subkutani ali intravenski injekciji.
administration of Victrelis
Victrelis in kvetiapina se
administration of Victrelis
Victrelis s sirolimusom
administration of Victrelis
Victrelis s takrolimusom
Administration of VIZAMYL and conduct of the procedure
Odmerjanje zdravila VIZAMYL in izvajanje postopka
Administration of VWF allows correction of the haemostatic abnormalities exhibited by patients who suffer from VWF deficiency (VWD) at two levels:
Dajanje VWF omogoča izboljšanje hemostatskih motenj, ki so prisotne pri bolnikih s pomanjkanjem VWF (VWB), na dveh ravneh:
Administration of Xofigo and conduct of the procedure
Uporaba zdravila Xofigo in potek postopka
Administration of ZALTRAP/FOLFIRI should be delayed until neutrophil count is 1.5 x 109/L (see section 4.2).
Uporabo sheme ZALTRAP/FOLFIRI je treba odložiti, dokler ni število nevtrofilcev  1,5 x 109/l (glejte poglavje 4.2).
Administration other than IV or IM
Aplikacija, različna od intravenske ali intramuskularne
Administration process
Postopek dajanja zdravila
administration site
premembe na mestu
administration site
Splošne težave in spremembe na mestu aplikacije
ADMINISTRATION SITE
SPREMEMBE NA MESTU
administration site conditions
mestu aplikacije
administration site conditions
na mestu aplikacije
administration site conditions
premembe na
administration site conditions
Splošne težave in spremembe na mestu aplikacije
ADMINISTRATION SYSTEM LABEL
NALEPKA NA APLIKACIJSKEM SISTEMU
Administration to both eyes concurrently is not recommended (see section 4.4).
Sočasno injiciranje v obe očesi ni priporočljivo (glejte poglavje 4.4).
Administration to both eyes concurrently is not recommended (see SmPC section 4.4).
Sočasno injiciranje v obe očesi ni priporočljivo (glejte poglavje 4.4 v Povzetku glavnih značilnosti zdravila).
Administration via Continuous Subcutaneous Insulin Infusion (CSII)
Apliciranje s kontinuiranim subkutanim infundiranjem insulina (CSII)
administration with
Klinične opombe
administration with
odmerjanja z
administration with
očasno uporabo z
administration with
uporabe z zdravilom
Administration with a syringe
Aplikacija z injekcijsko brizgo
Administration with a syringe
Injiciranje z injekcijsko brizgo
Administration with an insulin delivery system
Apliciranje s sistemom za dajanje insullina
administration with ddI+d4T
ddI+d4T (na tešče)
Administration with FlexPen
Injiciranje z injekcijskim peresnikom FlexPen
Administration with FlexTouch
Injiciranje z injekcijskim peresnikom FlexTouch
administration with food
uporabe skupaj s hrano
Administration with food may increase exposure to Lojuxta.
Zaužitje skupaj s hrano lahko poveča izpostavljenost zdravilu Lojuxta.
Administration with InnoLet
Aplikacija z injekcijskim peresnikom InnoLet
Administration with InnoLet
Injiciranje z injekcijskim peresnikom InnoLet
Administration with light meals (e.g., dry toast with jam or fruit conserve, apple juice, and coffee with skimmed or fat–free milk and sugar or corn flakes, skimmed or fat–free milk and sugar) resulted in plasma concentrations comparable to the corresponding fasted values.
Pri jemanju skupaj z lahkim obrokom (npr. prepečenec z marmelado ali konzerviranim sadjem, jabolčni sok in kava s posnetim mlekom ali mlekom brez maščobe in sladkor; koruzni kosmiči, posneto mleko ali mleko brez maščobe in sladkor) so bile plazemske koncentracije primerljive s tistimi po zaužitju na tešče.
administration with lopinavir/ritonavir.
trazodon, enkraten
Administration with other medicinal products
Uporaba z drugimi zdravili
Administration without food could be associated with a net loss of efficacy due to sub-optimal exposure.
Pri uporabi brez hrane bi se zaradi suboptimalne izpostavljenosti lahko zmanjšala učinkovitost zdravila.
administration)
merjena.
Administration-related reactions (ARRs) are known to occur with Herceptin subcutaneous formulation.
Znano je, da se pri dajanju subkutane oblike zdravila Herceptin pojavijo reakcije, povezane z aplikacijo.
Administration-related reactions (systemic non allergic)**
z dajanjem zdravila povezane reakcije (sistemske nealergijske)
administration.
afatinibom.
Administration:
Pot uporabe:
Administration: when reconstitution and dilution are performed under aseptic conditions ORENCIA infusion solution can be used immediately or within 24 hours if stored refrigerated at 2°C to 8°C. However, for microbiological reasons, it is to be used immediately.
Aplikacija: če sta rekonstitucija in redčenje izvedena v aseptičnih pogojih, se ORENCIA raztopino za infundiranje lahko uporabi takoj ali v 24 urah, če se jo shrani pri temperaturi od 2°C do 8°C, vendar pa jo je iz mikrobioloških razlogov bolje uporabiti takoj.
Administrator’s Instructions
Navodila za zdravstveno osebje
adnormal x-rays of the lungs (lung infiltration) plum-coloured, raised, painful sores on the limbs and sometimes the face and neck with fever (Sweets syndrome)
nenormalni rentgenski izvidi pljuč (pljučni infiltrati) boleče izbočene rane vijolične barve na okončinah in včasih na obrazu in vratu z zvišano telesno temperaturo (Sweetov sindrom)
Adolescent
mladostnik
Adolescents (12<18 years)
Mladostniki (12
Adolescents (9 to 17 years of age)
Mladostniki (9 do 17 let)
Adolescents (9 to 17 years of age)
Mladostniki (stari od 9 do 17 let)
Adolescents (9-<18 years)
Mladostniki (9-<18 let)
Adolescents (from 11 years of age) and adults should receive two injections.
Mladostniki (stari 11 let in več) in odrasli morajo prejeti dve injekciji.
Adolescents (from 11 years of age) and adults*
mladostniki (od 11 let starosti) in odrasli
Adolescents (N=49) 9 to 17 years of age
mladostniki (N=49) stari od 9 do 17 let
Adolescents 12 years of age and older, who weigh at least 35 kg: one tablet each day with food
Mladostniki, stari 12 let in več, s telesno maso vsaj 35 kg: ena tableta na dan s hrano
Adolescents 12 years of age and older, who weigh at least 35 kg: one tablet each day with food Do not chew, crush or split the tablet.
Mladostniki, stari 12 let ali več, s telesno maso vsaj 35 kg: ena tableta vsak dan s hrano Tablete ne žvečite, drobite in ne delite.
adolescents 12 years of age or older adults
mladostnike, stare 12 let in več, odrasle.
adolescents aged 12 to 17 years who have enthesitis-related arthritis and have not responded adequately to or cannot take standard treatment.
mladostnikih, starih od 12 do 17 let, ki imajo artritis, povezan z entezitisom in se niso ustrezno odzvali na standardno zdravljenje ali ga ne prenašajo.
Adolescents aged 12 to 17 years.
Mladostniki od 12 do 17 let.
adolescents aged 12 to less than 18 years who have already been treated with other HIV medicines which are no longer fully effective due to development of resistance, or have caused side effects.
mladostnike, stare 12 do manj kot 18 let, predhodno že zdravljene z drugimi zdravili proti HIV, ki niso več polno učinkovita zaradi nastanka odpornosti ali so povzročala neželene učinke.
Adolescents aged 12 to less than 18 years who weigh at least 35 kg: 1 tablet each day with food (for example, a meal or a snack).
mladostniki, stari 12 do manj kot 18 let, s telesno maso vsaj 35 kg: 1 tableta vsak dan s hrano (na primer ob obroku ali prigrizku).
adolescents aged 12 to less than 18 years.
mladostnike, stare 12 do manj kot 18 let.
Adolescents aged 13 years and older experienced side effects that were similar in frequency and type to those in adults except that sleepiness, uncontrollable twitching or jerking movements, restlessness, and tiredness were very common (may affect more than 1 in 10 patients) and upper abdominal pain, dry mouth, increased heart rate, weight gain, increased appetite, muscle twitching, uncontrolled movements of the limbs, and feeling dizzy, especially when getting up from a lying or sitting position, were common (may affect up to 1 in 10 patients).
Neželeni učinki pri mladostnikih, starih 13 let in starejših, so bili po pogostnosti in vrsti podobni neželenim učinkom pri odraslih, z izjemo naslednjih: zaspanost, nenadzorovani trzaji ali nehotni gibi, nemirnost in utrujenost, ki so bili zelo pogosti (pojavijo se lahko pri več kot 1 od 10 bolnikov), ter bolečina v zgornjem predelu trebuha, suha usta, hiter srčni utrip, povečanje telesne mase, povečan apetit, trzanje mišic, nenadzorovano gibanje udov in omotica, še posebej pri vstajanju iz ležečega ali sedečega položaja, ki so bili pogosti (pojavijo se lahko pri več kot 1 od 100 bolnikov).
Adolescents aged 13 years and older experienced side effects that were similar in frequency and type to those in adults except that sleepiness, uncontrollable twitching or jerking movements, restlessness, and tiredness were very common (may affect more than 1 in 10 people) and upper abdominal pain, dry mouth, increased heart rate, weight gain, increased appetite, muscle twitching, uncontrolled movements of the limbs, and feeling dizzy, especially when getting up from a lying or sitting position, were common (may affect up to 1 in 10 people).
Neželeni učinki pri mladostnikih, starih 13 let in starejših, so bili po pogostnosti in vrsti podobni neželenim učinkom pri odraslih, z izjemo naslednjih: zaspanost, nenadzorovani trzaji ali nehotni gibi, nemirnost in utrujenost, ki so bili zelo pogosti (pojavijo se lahko pri več kot 1 od 10 bolnikov), ter bolečina v zgornjem predelu trebuha, suha usta, hiter srčni utrip, povečanje telesne mase, povečan apetit, trzanje mišic, nenadzorovano gibanje udov in omotica, še posebej pri vstajanju iz ležečega ali sedečega položaja, ki so bili pogosti (pojavijo se lahko pri več kot 1 od 10 bolnikov).
Adolescents and adults 12-65 years
12 do 65 let
Adolescents and adults from 13 years of age
Mladostniki od 13. leta starosti in odrasli
Adolescents and children aged 2 years and older patients
Mladostniki in otroci, stari 2 leti in več
Adolescents, children and infants over the age of 3 months: the recommended oral dosage is
Mladostniki, otroci in dojenčki, starejši od treh mesecev: Priporočeno odmerjanje pri peroralni uporabi je
Adolescents, children and infants: total exposure to stavudine was comparable between adolescents, children and infants ≥ 14 days receiving the 2 mg/kg/day dose and adults receiving 1 mg/kg/day.
Mladostniki, otroci in dojenčki: Celotna izpostavljenost stavudinu je bila primerljiva pri mladostnikih, otrocih in dojenčkih ≥ 14 dni, ki so dobivali odmerek 2 mg/kg/dan, in odraslimi, ki so dobivali mg/kg/dan.
Adolescents: ellaOne is suitable for any woman of child bearing age, including adolescents.
Mladostnice: zdravilo ellaOne je primerno za vsako žensko v rodni dobi, vključno z mladostnicami.
Adolescents: the safety profile observed in women less than 18 years old in studies and post-marketing is similar to the safety profile in adults during the phase III program (Section 4.2).
Mladostnice: varnostni profil pri ženskah, starih manj kot 18 let, v študijah in v obdobju trženja, je podoben varnostnemu profilu pri odraslih v III. fazi programa (poglavje 4.2).
ADR frequency is based upon the following scale: Very Common (≥ 1/10); Common (≥ 1/100 -
Pogostost neželenih učinkov temelji na naslednji lestvici: zelo pogosti (≥1/10), pogosti (≥1/100 do
ADR identified post-marketing
neželeni učinki, odkriti v obdobju trženja
ADRa,b
Neželeni učinekab
Adrenal
Nadledvična žleza
Adrenal
Nadledvične žleze
Adrenal crisis as a cause of the patient’s symptoms must be excluded.
Pri bolniku je kot vzrok simptomov treba izključiti adrenalno krizo.
Adrenal function
Delovanje nadledvične žleze
Adrenal function
Delovanje nadledvičnih žlez
Adrenal function should be monitored at regular intervals since adrenal insuficiency can occur during the treatment under conditions of a relative cortisol deficiency due to an increased glucocorticoid demand (e.g. in case of stress, surgery, or infection); and/or in case of Ketoconazole HRA overtreatment (for the patients treated with a block-only regimen); or if there is insufficient glucocorticoid replacement therapy (for the patients treated with a block-and-replace regimen).
Delovanje nadledvične žleze je treba redno spremljati, saj se lahko med zdravljenjem pri pogojih relativnega pomanjkanja kortizola pojavi adrenalna insuficienca, ki je posledica povečane potrebe po glukokortikoidih (npr. pri stresu, kirurškem posegu ali okužbi) in/ali čezmernega zdravljenja z zdravilom Ketokonazol HRA (pri bolnikih, zdravljenih z režimom samo zaviranja) ali nezadostnega nadomestnega zdravljenja z glukokortikoidi (pri bolnikih, zdravljenih z režimom zaviranja in nadomeščanja).
Adrenal function”.
Delovanje nadledvičnih žlez".
Adrenal glands
Nadledvična žleza
adrenal glands not working properly – this may cause weakness, tiredness, loss of appetite, skin discolouration
nepravilno delovanje nadledvičnih žlez – to lahko povzroči šibkost, utrujenost, izgubo apetita, spremembo barve kože
Adrenal glands not working properly, inflammation of the thyroid gland
nepravilno delovanje nadledvičnih žlez, vnetje ščitnice
Adrenal haemorrhage
adrenalna krvavitev
Adrenal Insufficiency
Adrenalna insuficienca
adrenal insufficiency
insuficienca nadledvične žleze
Adrenal insufficiency
Oslabljeno delovanje nadledvične žleze
Adrenal insufficiency (including primary insufficiency or Addison’s disease) is a condition where the adrenal glands (located just above the kidneys) do not produce enough of a steroid hormone called cortisol (also known as the stress hormone because it is released in response to stress).
Adrenalna insuficienca (vključno s primarno insuficienco ali Addisonovo boleznijo) je stanje, pri katerem nadledvični žlezi (ki se nahajata nad ledvicama) ne proizvajata dovolj steroidnega hormona, imenovanega kortizol (znanega tudi kot stresni hormon, saj nastaja kot odziv na stres).
Adrenal insufficiency can require life-long treatment to replace the missing cortisol.
Adrenalna insuficienca lahko zahteva vseživljenjsko zdravljenje za nadomestitev manjkajočega kortizola.
Adrenal insufficiency may occur and can be a serious side effect.
Pojavi se lahko adrenalna insuficienca, ki je lahko resen neželeni učinek.
Adrenal insufficiency may occur in patients on ketoconazole without corticosteroid substitution (block-only regimen) or if there is an insufficient glucocorticoid replacement therapy (for the patients treated with a block- and-replace regimen).
Adrenalna insuficienca se lahko pojavi pri bolnikih, ki prejemajo ketokonazol brez nadomeščanja kortikosteroidov (režim samo z zaviranjem) ali pri katerih je nadomestno zdravljenje z glukokortikoidi nezadostno (režim z zaviranjem in nadomeščanjem).
Adrenal insufficiency*
adrenalna insuficienca
adrenal insufficiency, hypopituitarism, hypophysitis, hyperthyroidism, thyroiditis, hyperglycaemiab
insuficienca nadledvičnih žlez, hipopituitarizem, vnetje hipofize, hipertiroidizem, vnetje ščitnice, hiperglikemijab
adrenal insufficiency, hypopituitarism, hypophysitis, thyroiditis, diabetic ketoacidosis
insuficienca nadledvičnih žlez, hipopituitarizem, vnetje hipofize, vnetje ščitnice, diabetična ketoacidoza
adrenal insufficiency, hypothyroidism
adrenokortikalna insuficienca, hipotiroidizem
Adrenal insufficiency: fatigue, abdominal pain, nausea, vomiting, diarrhoea, confusion
oslabljeno delovanje nadledvične žleze: utrujenost, bolečine v trebuhu, slabost, bruhanje, driska, zmedenost;
adrenal insufficiencyc, secondary adrenocortical insufficiencyd, hyperthyroidismc, hypogonadism
insuficienca nadledvične žlezec, sekundarna insuficienca skorje nadledvične žlezed hipertiroidizemc, hipogonadizem
Adrenal insuficiency (diminution of the amount of hormones (cortisol)
adrenalna insuficienca (zmanjšanje količine hormonov (kortizola)),
adrenal steroid hormone such as cortisone or prednisolone
teroidne hormone nadledvične žleze, kot sta kortizon ali prednizolon
adrenaline and isoprenaline (both used for heart attacks) anticoagulants of the warfarin type (that prevent blood clotting).
adrenalinu in izoprenalinu (oboje se uporablja pri srčni kapi), antikoagulantih (preprečujejo strjevanje krvi) varfarinskega tipa.
adrenaline and isoprenaline (both used for heart attacks), anticoagulants of the warfarin type (that prevent blood clotting).
adrenalinu in izoprenalinu (oboje se uporablja pri srčni kapi), antikoagulantih (preprečujejo strjevanje krvi) varfarinskega tipa.
adrenaline and sympathicomimetics (to increase heart beat, to treat asthma or nasal congestion, coughs and colds or used in life-threatening emergencies)
adrenalin in simpatikomimetiki (za zvišanje srčnega utripa, za zdravljenje astme ali zamašenega nosu, kašlja in prehlada ali se uporabljajo v življenje-ogrožujočih nujnih primerih)